{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:40:40Z","timestamp":1761896440273,"version":"3.37.3"},"reference-count":16,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2017,1,30]],"date-time":"2017-01-30T00:00:00Z","timestamp":1485734400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2017,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The optimal regimen for peripheral blood stem cell (<jats:styled-content style=\"fixed-case\">PBSC<\/jats:styled-content>) mobilization in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation (auto\u2010<jats:styled-content style=\"fixed-case\">HCT<\/jats:styled-content>) has not been established. Experience at The University of Texas <jats:styled-content style=\"fixed-case\">MD<\/jats:styled-content> Anderson Cancer Center suggests in addition to single\u2010agent cyclophosphamide (Cy), modified cyclophosphamide, vincristine, doxorubicin, and dexamethasone (<jats:styled-content style=\"fixed-case\">mCVAD<\/jats:styled-content>), and modified cyclophosphamide, bortezomib, doxorubicin, and dexamethasone (<jats:styled-content style=\"fixed-case\">mCBAD<\/jats:styled-content>) may be successful chemomobilization regimens.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective review included 167 patients (66 with Cy, 74 with <jats:styled-content style=\"fixed-case\">mCVAD<\/jats:styled-content>, and 27 with <jats:styled-content style=\"fixed-case\">mCBAD<\/jats:styled-content>) with multiple myeloma undergoing mobilization for auto\u2010<jats:styled-content style=\"fixed-case\">HCT<\/jats:styled-content> between January 1, 2006 and September 30, 2013. The primary objective was to evaluate and compare the successful mobilization of <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>34+ cells among high\u2010dose Cy, <jats:styled-content style=\"fixed-case\">mCVAD<\/jats:styled-content> or <jats:styled-content style=\"fixed-case\">mCBAD<\/jats:styled-content>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Successful mobilization (\u22652\u00d710<jats:sup>6<\/jats:sup> <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>34+ cells\/kg) was achieved in all patients, while 65 (98%), 72 (97%), and 27 (100%) patients achieved an optimal mobilization (\u22654\u00d710<jats:sup>6<\/jats:sup> <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>34+ cells\/kg) in the Cy, <jats:styled-content style=\"fixed-case\">mCVAD<\/jats:styled-content>, and <jats:styled-content style=\"fixed-case\">mCBAD<\/jats:styled-content> groups, respectively. There was no significant difference in the number of apheresis sessions (<jats:italic>P<\/jats:italic>=.63), incidence of febrile neutropenia (<jats:italic>P<\/jats:italic>=.57), or hospital admission rates (<jats:italic>P<\/jats:italic>=.55).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Either Cy, <jats:styled-content style=\"fixed-case\">mCVAD<\/jats:styled-content>, or <jats:styled-content style=\"fixed-case\">mCBAD<\/jats:styled-content> can yield successful <jats:styled-content style=\"fixed-case\">PBSC<\/jats:styled-content> mobilization in patients with multiple myeloma undergoing auto\u2010HCT.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.12843","type":"journal-article","created":{"date-parts":[[2016,12,25]],"date-time":"2016-12-25T04:10:19Z","timestamp":1482639019000},"page":"388-392","source":"Crossref","is-referenced-by-count":12,"title":["Modified <scp>CVAD<\/scp> and modified <scp>CBAD<\/scp> compared to high\u2010dose cyclophosphamide for peripheral blood stem cell mobilization in patients with multiple myeloma"],"prefix":"10.1111","volume":"98","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6682-2160","authenticated-orcid":false,"given":"Suzanne C.","family":"Gettys","sequence":"first","affiliation":[{"name":"Division of Pharmacy The University of Texas MD Anderson Cancer Center  Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison","family":"Gulbis","sequence":"additional","affiliation":[{"name":"Division of Pharmacy The University of Texas MD Anderson Cancer Center  Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaci","family":"Wilhelm","sequence":"additional","affiliation":[{"name":"McKesson Corporation  Santa Barbara CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy The University of Texas MD Anderson Cancer Center  Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvonne","family":"Dinh","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy The University of Texas MD Anderson Cancer Center  Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela","family":"Rondon","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy The University of Texas MD Anderson Cancer Center  Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muzaffar H.","family":"Qazilbash","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Transplantation and Cellular Therapy The University of Texas MD Anderson Cancer Center  Houston TX USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,1,30]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70442-5"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1011442"},{"key":"e_1_2_5_4_1","unstructured":"National Comprehensive Cancer Network. Multiple Myeloma (Version 3.2016).https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/myeloma.pdf. Accessed September 28 2016."},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-08-174946"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2012.01.008"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.4.1547"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2012.06.008"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1700867"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8652(199606)52:2<77::AID-AJH2>3.0.CO;2-2"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.7.2059"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-199808000-00019"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2012.01.005"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2008.12.512"},{"key":"e_1_2_5_15_1","first-page":"w13203","article-title":"Validation of prognostic factors and survival of patients with multiple myeloma in a real\u2010life autologous stem cell transplantation setting: a Swiss single centre experience","volume":"141","author":"Samaras P","year":"2011","journal-title":"Swiss Med Wkly"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2009.176"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2011.82"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fejh.12843","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.12843","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T23:34:31Z","timestamp":1695512071000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.12843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,30]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["10.1111\/ejh.12843"],"URL":"https:\/\/doi.org\/10.1111\/ejh.12843","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"type":"print","value":"0902-4441"},{"type":"electronic","value":"1600-0609"}],"subject":[],"published":{"date-parts":[[2017,1,30]]}}}